These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 839365)

  • 1. Suppressibility of glucagon secretion by glucose in juvenile diabetes.
    Sperling MA; Aleck K; Voina S
    J Pediatr; 1977 Apr; 90(4):543-7. PubMed ID: 839365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
    Saccà L; Sherwin R; Hendler R; Felig P
    J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of insulin on the response of immunoreactive glucagon to an intravenous glucose load in human diabetes.
    Yamamoto T; Raskin P; Aydin I; Unger R
    Metabolism; 1979 May; 28(5):568-74. PubMed ID: 449698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient diabetes mellitus in a neonate. Evaluation of insulin, glucagon, and growth hormone secretion and management with a continuous low-dose insulin infusion.
    Sodoyez-Goffaux F; Sodoyez JC
    J Pediatr; 1977 Sep; 91(3):395-9. PubMed ID: 894407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of hyperglucagonemia on blood glucose concentrations and on insulin requirements in insulin-requiring diabetes mellitus.
    Clarke WL; Santiago JV; Kipnis DM
    Diabetes; 1978 Jun; 27(6):649-52. PubMed ID: 658610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes.
    Raskin P; Unger RH
    N Engl J Med; 1978 Aug; 299(9):433-6. PubMed ID: 683275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects.
    Sherwin RS; Fisher M; Hendler R; Felig P
    N Engl J Med; 1976 Feb; 294(9):455-61. PubMed ID: 1246330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressible glucagon secretion in young, ketosis-resistant, type "J" diabetic patients in India.
    Rao RH; Vigg BL; Rao KS
    Diabetes; 1983 Dec; 32(12):1168-71. PubMed ID: 6418596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon suppression with low-dose intramuscular insulin therapy in diabetic ketoacidosis.
    Onur K; Lala VR; Juan CS; AvRuskin TW
    J Pediatr; 1979 Feb; 94(2):307-11. PubMed ID: 105114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nocturnal blood glucose control in type I diabetes mellitus.
    Bolli GB; Perriello G; Fanelli CG; De Feo P
    Diabetes Care; 1993 Dec; 16 Suppl 3():71-89. PubMed ID: 8299480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.
    Hare KJ; Vilsbøll T; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2010 Apr; 298(4):E832-7. PubMed ID: 20103744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration.
    Starke A; Imamura T; Unger RH
    J Clin Invest; 1987 Jan; 79(1):20-4. PubMed ID: 2878938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus.
    Sakurai H; Dobbs RE; Unger RH
    Metabolism; 1975 Nov; 24(11):1287-97. PubMed ID: 1186499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose, insulin, pancreatic glucagon and glucagon-like immunoreactive materials in the plasma of normal and diabetic children. Effect of the initial insulin treatment.
    Matsuyama T; Hoffman WH; Dunbar JC; Foà NL; Foà PP
    Horm Metab Res; 1975 Nov; 7(6):452-6. PubMed ID: 1213649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
    Gerich JE; Lorenzi M; Bier DM; Tsalikian E; Schneider V; Karam JH; Forsham PH
    J Clin Invest; 1976 Apr; 57(4):875-84. PubMed ID: 820717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus.
    Gerich JE; Langlois M; Noacco C; Lorenzi M; Karam JH; Korsham PH
    J Clin Invest; 1976 Aug; 58(2):320-5. PubMed ID: 783198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin.
    Sherwin RS; Hendler R; DeFronzo R; Wahren J; Felic P
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):348-52. PubMed ID: 264686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of somatostatin on blood sugar, plasma growth hormone, and glucagon levels in diabetic children.
    Del Guercio MJ; di Natale B; Gargantini L; Garlaschi C; Chiumello G
    Diabetes; 1976 Jul; 25(7):550-3. PubMed ID: 1278605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.